Berger Montague (Canada), P.C. is a professional corporation registered with the Province of Ontario, and regulated by the Law Society of Ontario. 

During 2023, Albert Pelletier and Andrew Morganti founded Berger Montague (Canada) PC as an affiliate of Berger Montague PC, one of the United States’ premier litigation law firms that represents individual, businesses, organizations, and government entities as plaintiffs in individual and class actions.

We provide domestic and foreign-based investors in courts across North America and Europe. The Firm routinely represents institutional and retail investors in Canada, England, France, Germany, Netherlands, and the United States. We have extensive experience in cross-border antitrust and securities litigation. We act for individuals, family offices, and pension funds in a wide array of shareholder disputes.

Our lawyers have acted in some of the largest securities class actions in Canada and the United States.  Our ongoing plaintiff-side securities litigation are those identified on our Featured Securities Litigation page and our lawyers were involved in many important securities class actions in Canada and the United States including those against Amaya Inc., Concordia International Corp., FSD Pharma. Inc., Valeant Pharmaceuticals International Inc., and the In re Initial Public Offering Securities Litigationand representing business owners that sold their companies in exchange for stock of the acquiring company that turned out to be worth substantially less than represented, such as in WyldFyre Technologies v. Homestore.com, Inc. and successfully advanced claims relating to tainted research reports.  We believe that we have one of the most proactive practices representing shareholders in disputes relating to investments in Cannabis Companies across Canada.

For further information about our securities litigation practice, please contact Albert Pelletier (Provincial, Canadian) or Andrew Morganti (Cross-Border).

On the Cutting Edge of the Profession

Legal Intelligencer